Research programme: MKC 1106 immunotherapies - Colby Pharmaceutical/MannKind Corporation

Drug Profile

Research programme: MKC 1106 immunotherapies - Colby Pharmaceutical/MannKind Corporation

Alternative Names: MKC 1106-NS; MKC1106 active immunotherapies

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MannKind Corporation
  • Developer Colby Pharmaceuticals; MannKind Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Haematological malignancies; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Intralymphatic)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (Intralymphatic, Injection)
  • 13 Nov 2012 MKC 1106 immunotherapy programme licensed to Colby Pharmaceutical Company worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top